Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
monoclonal antibodies
Biotech
Amgen reveals 6-point drop in lupus severity behind ph. 2 win
Amgen has shed light on its phase 2 lupus win, revealing that daxdilimab was tied to a 6-point reduction in disease severity at the lower dose.
James Waldron
Sep 30, 2026 4:26am
Tolerance continues thymus-focused deals with $560M Tanabe pact
Sep 28, 2026 8:59am
Regeneron ends eye disease trial following safety review
Aug 17, 2026 2:30pm
US taps small biotech for experimental Ebola treatment
May 20, 2026 7:18pm
New antibodies stop measles from stabbing cells, study finds
May 7, 2026 11:00am
New biotech Slate aims to solve migraine injection equation
Feb 24, 2026 7:30am
